ArticleKidney diseases (Basel, Switzerland)
Immunological Characteristics of Chinese Adult Patients with Anti-Complement Factor H Autoantibodies-Associated Complement-Mediated Thrombotic Microangiopathy.
Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anti-complement factor H autoantibodies (FHAAs)-associated complement-mediated thrombotic microangiopathy (CM-TMA) is prevalent in pediatric patients and plays an important role in the pathogenesis of CM-TMA. The epitopes of FHAAs in adult CM-TMA patients remain to be explored. Methods: A total of 114 adult patients with CM-TMA were enrolled. Their clinicopathological data as well as plasma samples were collected. Seven CFH fragments covering different short consensus repeats (SCRs) of factor H were expressed by HEK293 or ExpiCHO cells. The presence of FHAAs and the antigenic epitopes were detected by using enzyme-linked immunosorbent assay. Results: FHAAs were detected in 10 of the adult patients with CM-TMA. The main epitope of FHAAs was SCRs 15-20 (88.89%, 8/9). The prevalence of anti-SCRs 1-4, anti-SCRs 1-6, anti-SCRs 5-7, anti-SCR 7, anti-SCRs 11-14, and anti-SCRs 19-20 autoantibodies was 22.22% (2/9), 0% (0/9), 33.33% (3/9), 11.11% (1/9), 0% (0/9), and 44.44% (4/9), respectively. The levels of anti-SCRs 15-20 autoantibodies were significantly decreased in the remission phase compared with that in the active phase (107.49 ± 36.8 AU/mL vs. 181.52 ± 33.62 AU/mL, Conclusion: FHAAs were positive in 8.77% (10/114) of adult CM-TMA patients and SCRs 15-20 might be the main epitope of FHAAs in FHAA-associated CM-TMA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.